Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chemotherapy-Induced Peripheral Neuropathy from 2016 to 2027 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Chemotherapy-Induced Peripheral Neuropathy - Disease Understanding and Treatment Algorithm
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. With the exception of paclitaxel and oxaliplatin, which cause an acute neuropathy that emerges either during or shortly after infusion, the onset of CIPN is usually delayed and appears to depend on the total cumulative dose. Clinically, CIPN presents as deficits in sensory, motor, and autonomic function which develop in a compound-specific manner.
The DelveInsight Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report gives the thorough understanding of the CIPN by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CIPN in the US, Europe, Japan and China.
Chemotherapy-Induced Peripheral Neuropathy Epidemiology
The Chemotherapy-Induced Peripheral Neuropathy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CIPN, Severity Specific Incident Population of CIPN and Incident Population of CIPN by Chemotherapeutic Agents] scenario of Chemotherapy-Induced Peripheral Neuropathy in the G8 coutries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
According to DelveInsight, incident population of CIPN in the G8 countries is expected to increase at a CAGR of 0.35% for the study period i.e. 2016-2027. DelveInsight estimates show higher incidence of CIPN in China with 1,542,149 cases in 2016, due to the higher incidence of cancer than US, EU5 and Japan. Among the European countries, Germany had the highest incident population of CIPN, followed by the United Kingdom in 2016. On the other hand, Spain had the lowest incident population of nearly 80,000 in 2016. According to DelveInsight, majority of the CIPN cases is caused by the platinum-based chemotherapeutic agents such as oxaliplatin and cisplatin, followed by taxane agents. Furthermore, assessments show that in terms of severity, the majority of the patients have been diagnosed with moderate and severe forms of CIPN, while mild CIPN cases were also diagnosed. In 2016, incident cases of mild, moderate and severe CIPN in the US varied in the range 100,000 to 300,000. This trend is expected to be followed during the forecast period [2018-2027].
Chemotherapy-Induced Peripheral Neuropathy Drug Chapters
This segment of the Chemotherapy-Induced Peripheral Neuropathy (CIPN) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market size of CIPN depends entirely on the type of nerve damage, symptoms, and location. Currently, there is no approved therapy for the treatment of CIPN. The current therapeutic landscape of CIPN worldwide is dependent on off-label therapies, used to reduce the symptoms in CIPN patients. Guidelines for the prevention and management of CIPN in survivors of adult cancers, have reported pharmacologic treatment of neuropathic pain developed with a consensus that alpha-2-delta antagonist (anticonvulsants), serotonin-norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics are good treatment options for neuropathic pain.
Detailed chapters of upcoming therapies such as SP-04 (PledOx; Solasia), Tetrodotoxin (TTX; WEX Pharmaceuticals) and E-52862 (Esteve), which are expected to launch during the forecast period [2018-2027] have also been covered in the report.
Chemotherapy-Induced Peripheral Neuropathy Market Outlook
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN. Among the different classes of therapies which are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Many companies are aggressively working towards the development of targeted therapies for CIPN such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo Endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others. Of the aforementioned pharmaceutical companies, targeted products by Solasia (SP-04), WEX Pharmaceuticals (Tetrodotoxin) and Esteve (E-52862) are expected to be launched during the forecast period [2018-2027]. It has been assessed that SP-04 holds the highest expectations of analysts. Despite the launch E-52862 (Esteve) later than Tetrodotoxin (TTX; WEX Pharmaceuticals), E-52862 is predicted to create comparatively greater impact on the market size of CIPN. This may be attributed to the target-specific mechanism of E-52862 for CIPN, while Tetrodotoxin will be launched by WEX Pharmaceuticals, for overall neuropathic pain.
Chemotherapy-Induced Peripheral Neuropathy Report Insights
DelveInsight’s ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chemotherapy-Induced Peripheral Neuropathy from 2016 to 2027 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
- China
Chemotherapy-Induced Peripheral Neuropathy - Disease Understanding and Treatment Algorithm
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. With the exception of paclitaxel and oxaliplatin, which cause an acute neuropathy that emerges either during or shortly after infusion, the onset of CIPN is usually delayed and appears to depend on the total cumulative dose. Clinically, CIPN presents as deficits in sensory, motor, and autonomic function which develop in a compound-specific manner.
The DelveInsight Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report gives the thorough understanding of the CIPN by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CIPN in the US, Europe, Japan and China.
Chemotherapy-Induced Peripheral Neuropathy Epidemiology
The Chemotherapy-Induced Peripheral Neuropathy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CIPN, Severity Specific Incident Population of CIPN and Incident Population of CIPN by Chemotherapeutic Agents] scenario of Chemotherapy-Induced Peripheral Neuropathy in the G8 coutries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
According to DelveInsight, incident population of CIPN in the G8 countries is expected to increase at a CAGR of 0.35% for the study period i.e. 2016-2027. DelveInsight estimates show higher incidence of CIPN in China with 1,542,149 cases in 2016, due to the higher incidence of cancer than US, EU5 and Japan. Among the European countries, Germany had the highest incident population of CIPN, followed by the United Kingdom in 2016. On the other hand, Spain had the lowest incident population of nearly 80,000 in 2016. According to DelveInsight, majority of the CIPN cases is caused by the platinum-based chemotherapeutic agents such as oxaliplatin and cisplatin, followed by taxane agents. Furthermore, assessments show that in terms of severity, the majority of the patients have been diagnosed with moderate and severe forms of CIPN, while mild CIPN cases were also diagnosed. In 2016, incident cases of mild, moderate and severe CIPN in the US varied in the range 100,000 to 300,000. This trend is expected to be followed during the forecast period [2018-2027].
Chemotherapy-Induced Peripheral Neuropathy Drug Chapters
This segment of the Chemotherapy-Induced Peripheral Neuropathy (CIPN) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market size of CIPN depends entirely on the type of nerve damage, symptoms, and location. Currently, there is no approved therapy for the treatment of CIPN. The current therapeutic landscape of CIPN worldwide is dependent on off-label therapies, used to reduce the symptoms in CIPN patients. Guidelines for the prevention and management of CIPN in survivors of adult cancers, have reported pharmacologic treatment of neuropathic pain developed with a consensus that alpha-2-delta antagonist (anticonvulsants), serotonin-norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics are good treatment options for neuropathic pain.
Detailed chapters of upcoming therapies such as SP-04 (PledOx; Solasia), Tetrodotoxin (TTX; WEX Pharmaceuticals) and E-52862 (Esteve), which are expected to launch during the forecast period [2018-2027] have also been covered in the report.
Chemotherapy-Induced Peripheral Neuropathy Market Outlook
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN. Among the different classes of therapies which are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Many companies are aggressively working towards the development of targeted therapies for CIPN such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo Endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others. Of the aforementioned pharmaceutical companies, targeted products by Solasia (SP-04), WEX Pharmaceuticals (Tetrodotoxin) and Esteve (E-52862) are expected to be launched during the forecast period [2018-2027]. It has been assessed that SP-04 holds the highest expectations of analysts. Despite the launch E-52862 (Esteve) later than Tetrodotoxin (TTX; WEX Pharmaceuticals), E-52862 is predicted to create comparatively greater impact on the market size of CIPN. This may be attributed to the target-specific mechanism of E-52862 for CIPN, while Tetrodotoxin will be launched by WEX Pharmaceuticals, for overall neuropathic pain.
Chemotherapy-Induced Peripheral Neuropathy Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Years Forecast
- G8 Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chemotherapy-Induced Peripheral Neuropathy market
- Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-Induced Peripheral Neuropathy market
- To understand the future market competition in the Chemotherapy-Induced Peripheral Neuropathy market.
1. KEY INSIGHTS
2. CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2016
2.2. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2027
2.3. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy by therapies in 2016
2.4. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy by therapies in 2027
3. CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
3.3. Symptoms of CIPN
3.4. Grading of chemotherapy-induced peripheral neuropathy
3.5. Pathophysiology of CIPN
3.6. Chemotherapy-Induced Peripheral Neuropathy: Clinical Presentation
3.7. Genetics of chemotherapy-induced peripheral neuropathy
3.8. Diagnosis of CIPN
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Incident Population of CIPN in G8
5. COUNTRY WISE-EPIDEMIOLOGY OF CIPN
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Incident Population of CIPN in the United States
5.1.3. Severity Specific Incident Population of CIPN in the United States
5.1.4. Incident Population of CIPN by Chemotherapeutic Agents in the United States
5.2. EU5 countries
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Total Incident Population of CIPN in Germany
5.3.2. Severity Specific Incident Population of CIPN in Germany
5.3.3. Incident Population of CIPN by Chemotherapeutic Agents in Germany
5.4. France
5.4.1. Total Incident Population of CIPN in France
5.4.2. Severity Specific Incident Population of CIPN in France
5.4.3. Incident Population of CIPN by Chemotherapeutic Agents in France
5.5. Italy
5.5.1. Total Incident Population of CIPN in Italy
5.5.2. Severity Specific Incident Population of CIPN in Italy
5.5.3. Incident Population of CIPN by Chemotherapeutic Agents in Italy
5.6. Spain
5.6.1. Total Incident Population of CIPN in Spain
5.6.2. Severity Specific Incident Population of CIPN in Spain
5.6.3. Incident Population of CIPN by Chemotherapeutic Agents in Spain
5.7. United Kingdom
5.7.1. Total Incident Population of CIPN in the United Kingdom
5.7.2. Severity Specific Incident Population of CIPN in the United Kingdom
5.7.3. Incident Population of CIPN by Chemotherapeutic Agents in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Total Incident Population of CIPN in the Japan
5.8.3. Severity Specific Incident Population of CIPN in the Japan
5.8.4. Incident Population of CIPN by Chemotherapeutic Agents in the Japan
5.9. China
5.9.1. Assumptions and Rationale
5.9.2. Total Incident Population of CIPN in China
5.9.3. Severity Specific Incident Population of CIPN in China
5.9.4. Incident Population of CIPN by Chemotherapeutic Agents in China
6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
6.1. Preventive Drugs for CIPN
6.2. Symptomatic Treatment of CIPN
6.2.1. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
6.2.2. Guidelines for the Pharmacologic Management of Neuropathic Pain: Japan
7. UNMET NEEDS
8. EMERGING THERAPIES
8.1. Key Cross Competition
8.2. SP-04 (PledOx): Solasia/PledPharma
8.2.1. Product Description
8.2.2. Other Developmental Activities
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Tetrodotoxin or TTX: WEX Phamaceuticals
8.3.1. Product Description
8.3.2. Other Developmental Activities
8.3.3. Clinical Development
8.3.4. Product Profile
8.4. E-52862: Laboratorios Dr. Esteve S.A. (ESTEVE)
8.4.1. Product Description
8.4.2. Other Developmental Activities
8.4.3. Clinical Development
8.4.4. Safety and Efficacy
8.4.5. Product Profile
8.5. ART-123 (Thrombomodulin alfa): Asahi Kasei Pharma
8.5.1. Product Description
8.5.2. Other Developmental Activities
8.5.3. Product Profile
8.6. MN-166 (Ibudilast): MediciNova
8.6.1. Product Description
8.6.2. Other Developmental Activities
8.6.3. Clinical Development
8.6.4. Safety and Efficacy
8.6.5. Product Profile
8.7. Topofen: Achelios Therapeutics
8.7.1. Product Description
8.7.2. Other Developmental Activities
8.7.3. Product Profile
8.8. KRN 5500: DARA BioSciences
8.8.1. Product Description
8.8.2. Other Developmental Activities
8.8.3. Clinical Development
8.8.4. Safety and Efficacy
8.8.5. Advantages and Disadvantages
8.8.6. Product Profile
8.9. NIAGEN: ChromaDex
8.9.1. Product Description
8.9.2. Clinical Development
8.9.3. Safety and Efficacy
8.9.4. Product Profile
8.10. Atexakin alfa: Relief Therapeutics
8.10.1. Product Description
8.10.2. Clinical Development
8.10.3. Product Profile
8.11. Lpathomab: Apollo Endosurgery
8.11.1. Product Description
8.11.2. Other Developmental Activities
8.11.3. Clinical Development
9. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: G8 MARKET ANALYSIS
9.1. Key Findings
9.2. Market Size of Chemotherapy Induced Peripheral Neuropathy in G8 countries
9.3. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in G8 Countries
10. UNITED STATES: MARKET OUTLOOK
10.1. United States Market Size
10.1.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
10.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in the US
11. EU-5 COUNTRIES: MARKET OUTLOOK
11.1. Germany Market Size
11.1.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Germany
11.2. France Market Size
11.2.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.2.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in France
11.3. Italy Market Size
11.3.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.3.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Italy
11.4. Spain Market Size
11.4.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.4.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Spain
11.5. United Kingdom Market Size
11.5.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.5.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in the UK
12. JAPAN MARKET OUTLOOK
12.1. Japan Market Size
12.1.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
12.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Japan
13. CHINA MARKET OUTLOOK
13.1. China Market Size
13.1.1. Total Market Size of Chemotherapy Induced Peripheral Neuropathy in China
13.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in China
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
16.1. Report Methodology
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2016
2.2. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2027
2.3. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy by therapies in 2016
2.4. Total Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy by therapies in 2027
3. CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
3.3. Symptoms of CIPN
3.4. Grading of chemotherapy-induced peripheral neuropathy
3.5. Pathophysiology of CIPN
3.6. Chemotherapy-Induced Peripheral Neuropathy: Clinical Presentation
3.7. Genetics of chemotherapy-induced peripheral neuropathy
3.8. Diagnosis of CIPN
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Incident Population of CIPN in G8
5. COUNTRY WISE-EPIDEMIOLOGY OF CIPN
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Incident Population of CIPN in the United States
5.1.3. Severity Specific Incident Population of CIPN in the United States
5.1.4. Incident Population of CIPN by Chemotherapeutic Agents in the United States
5.2. EU5 countries
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Total Incident Population of CIPN in Germany
5.3.2. Severity Specific Incident Population of CIPN in Germany
5.3.3. Incident Population of CIPN by Chemotherapeutic Agents in Germany
5.4. France
5.4.1. Total Incident Population of CIPN in France
5.4.2. Severity Specific Incident Population of CIPN in France
5.4.3. Incident Population of CIPN by Chemotherapeutic Agents in France
5.5. Italy
5.5.1. Total Incident Population of CIPN in Italy
5.5.2. Severity Specific Incident Population of CIPN in Italy
5.5.3. Incident Population of CIPN by Chemotherapeutic Agents in Italy
5.6. Spain
5.6.1. Total Incident Population of CIPN in Spain
5.6.2. Severity Specific Incident Population of CIPN in Spain
5.6.3. Incident Population of CIPN by Chemotherapeutic Agents in Spain
5.7. United Kingdom
5.7.1. Total Incident Population of CIPN in the United Kingdom
5.7.2. Severity Specific Incident Population of CIPN in the United Kingdom
5.7.3. Incident Population of CIPN by Chemotherapeutic Agents in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Total Incident Population of CIPN in the Japan
5.8.3. Severity Specific Incident Population of CIPN in the Japan
5.8.4. Incident Population of CIPN by Chemotherapeutic Agents in the Japan
5.9. China
5.9.1. Assumptions and Rationale
5.9.2. Total Incident Population of CIPN in China
5.9.3. Severity Specific Incident Population of CIPN in China
5.9.4. Incident Population of CIPN by Chemotherapeutic Agents in China
6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
6.1. Preventive Drugs for CIPN
6.2. Symptomatic Treatment of CIPN
6.2.1. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
6.2.2. Guidelines for the Pharmacologic Management of Neuropathic Pain: Japan
7. UNMET NEEDS
8. EMERGING THERAPIES
8.1. Key Cross Competition
8.2. SP-04 (PledOx): Solasia/PledPharma
8.2.1. Product Description
8.2.2. Other Developmental Activities
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Tetrodotoxin or TTX: WEX Phamaceuticals
8.3.1. Product Description
8.3.2. Other Developmental Activities
8.3.3. Clinical Development
8.3.4. Product Profile
8.4. E-52862: Laboratorios Dr. Esteve S.A. (ESTEVE)
8.4.1. Product Description
8.4.2. Other Developmental Activities
8.4.3. Clinical Development
8.4.4. Safety and Efficacy
8.4.5. Product Profile
8.5. ART-123 (Thrombomodulin alfa): Asahi Kasei Pharma
8.5.1. Product Description
8.5.2. Other Developmental Activities
8.5.3. Product Profile
8.6. MN-166 (Ibudilast): MediciNova
8.6.1. Product Description
8.6.2. Other Developmental Activities
8.6.3. Clinical Development
8.6.4. Safety and Efficacy
8.6.5. Product Profile
8.7. Topofen: Achelios Therapeutics
8.7.1. Product Description
8.7.2. Other Developmental Activities
8.7.3. Product Profile
8.8. KRN 5500: DARA BioSciences
8.8.1. Product Description
8.8.2. Other Developmental Activities
8.8.3. Clinical Development
8.8.4. Safety and Efficacy
8.8.5. Advantages and Disadvantages
8.8.6. Product Profile
8.9. NIAGEN: ChromaDex
8.9.1. Product Description
8.9.2. Clinical Development
8.9.3. Safety and Efficacy
8.9.4. Product Profile
8.10. Atexakin alfa: Relief Therapeutics
8.10.1. Product Description
8.10.2. Clinical Development
8.10.3. Product Profile
8.11. Lpathomab: Apollo Endosurgery
8.11.1. Product Description
8.11.2. Other Developmental Activities
8.11.3. Clinical Development
9. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: G8 MARKET ANALYSIS
9.1. Key Findings
9.2. Market Size of Chemotherapy Induced Peripheral Neuropathy in G8 countries
9.3. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in G8 Countries
10. UNITED STATES: MARKET OUTLOOK
10.1. United States Market Size
10.1.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
10.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in the US
11. EU-5 COUNTRIES: MARKET OUTLOOK
11.1. Germany Market Size
11.1.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Germany
11.2. France Market Size
11.2.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.2.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in France
11.3. Italy Market Size
11.3.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.3.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Italy
11.4. Spain Market Size
11.4.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.4.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Spain
11.5. United Kingdom Market Size
11.5.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
11.5.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in the UK
12. JAPAN MARKET OUTLOOK
12.1. Japan Market Size
12.1.1. Total Market size of Chemotherapy Induced Peripheral Neuropathy
12.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in Japan
13. CHINA MARKET OUTLOOK
13.1. China Market Size
13.1.1. Total Market Size of Chemotherapy Induced Peripheral Neuropathy in China
13.1.2. Market Size of Chemotherapy Induced Peripheral Neuropathy by therapies in China
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
16.1. Report Methodology
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Common signs and symptoms observed in patients with chemotherapy-induced peripheral neuropathies
Table 2: Grading scales for chemotherapy-Induced Peripheral Neuropathy
Table 3: Characteristics of the peripheral neurotoxicity caused by the most frequently used antineoplastic agents
Table 4: Core Diagnostic Criteria for Chemotherapy-Induced Peripheral Neuropathy
Table 5: Evaluations that should be performed prior to prescribing an analgesic in elderly patients
Table 6: Total Incident Population of CIPN in the G8 Countries (2016-2027)
Table 7: Total Incident Population of CIPN in the US (2016-2027)
Table 8: Severity Specific Incidence of CIPN in the US (2016-2027)
Table 9: Incident Population of CIPN by Chemotherapeutic Agents in the US (2016-2027)
Table 10: Total Incident Population of CIPN in Germany (2016-2027)
Table 11: Severity Specific Incidence of CIPN in Germany (2016-2027)
Table 12: Incident Population of CIPN by Chemotherapeutic Agents in Germany (2016-2027)
Table 13: Total Incident Population of CIPN in France (2016-2027)
Table 14: Severity Specific Incidence of CIPN in France (2016-2027)
Table 15: Incident Population of CIPN by Chemotherapeutic Agents in France (2016-2027)
Table 16: Total Incident Population of CIPN in Italy (2016-2027)
Table 17: Severity Specific Incidence of CIPN in Italy (2016-2027)
Table 18: Incident Population of CIPN by Chemotherapeutic Agents in Italy (2016-2027)
Table 19: Total Incident Population of CIPN in Spain (2016-2027)
Table 20: Severity Specific Incidence of CIPN in Spain (2016-2027)
Table 21: Incident Population of CIPN by Chemotherapeutic Agents in Spain (2016-2027)
Table 22: Total Incident Population of CIPN in the UK (2016-2027)
Table 23: Severity Specific Incidence of CIPN in the UK (2016-2027)
Table 24: Incident Population of CIPN by Chemotherapeutic Agents in the UK (2016-2027)
Table 25: Total Incident Population of CIPN in the Japan (2016-2027)
Table 26: Severity Specific Incidence of CIPN in the Japan (2016-2027)
Table 27: Incident Population of CIPN by Chemotherapeutic Agents in the Japan (2016-2027)
Table 28: Total Incident Population of CIPN in China (2016-2027)
Table 29: Severity Specific Incidence of CIPN in China (2016-2027)
Table 30: Incident Population of CIPN by Chemotherapeutic Agents in China (2016-2027)
Table 31: Guidelines for the Treatment for CIPN: American Society of Clinical Oncology Clinical Practice
Table 32: Guidelines for the Pharmacologic Management of Neuropathic Pain
Table 33: Advantages and disadvantages of analgesics
Table 34: Initial and maximum doses of agents used to treat NeP based on the recommendations by the JSPC 2016 and IASP 2007
Table 35: Emerging Drugs Analysis
Table 36: Emerging Drugs Analysis (Continued)
Table 37: Emerging Drugs Analysis (Continued)
Table 38: Emerging Drugs Analysis (Continued)
Table 39: SP-04 (PledOx),Clinical Trial Description, 2018
Table 40: Tetrodotoxin (TTX),Clinical Trial Description, 2018
Table 41: E-52862, Clinical Trial Description, 2018
Table 42: KRN5500,Clinical Trial Description, 2018
Table 43: NIAGEN, Clinical Trial Description, 2018
Table 44: Market Size of CIPN in G8 Countries in USD Million (2016-2027)
Table 45: Market Size of CIPN by therapies in G8 Countries in USD Million (2016-2027)
Table 46: The US Market Size of CIPN in USD Million (2016-2027)
Table 47: Market Size of CIPN by therapies in the US in USD Million (2016-2027)
Table 48: Germany Market Size of CIPN in USD Million (2016-2027)
Table 49: Market Size of CIPN by therapies in Germany in USD Million (2016-2027)
Table 50: France Market Size of CIPN in USD Million (2016-2027)
Table 51: Market Size of CIPN by therapies in France in USD Million (2016-2027)
Table 52: Italy Market Size of CIPN in USD Million (2016-2027)
Table 53: Market Size of CIPN by therapies in Italy in USD Million (2016-2027)
Table 54: Spain Market Size of CIPN in USD Million (2016-2027)
Table 55: Market Size of CIPN by therapies in Spain in USD Million (2016-2027)
Table 56: The UK Market Size of CIPN in USD Million (2016-2027)
Table 57: Market Size of CIPN by therapies in the UK in USD Million (2016-2027)
Table 58: Japan Market Size of CIPN in USD Million (2016-2027)
Table 59: Market Size of CIPN by therapies in Japan in USD Million (2016-2027)
Table 60: Market Size of CIPN in China, in USD Million (2016-2027)
Table 61: Market Size of CIPN by therapies in China in USD Million (2016-2027)
Table 1: Common signs and symptoms observed in patients with chemotherapy-induced peripheral neuropathies
Table 2: Grading scales for chemotherapy-Induced Peripheral Neuropathy
Table 3: Characteristics of the peripheral neurotoxicity caused by the most frequently used antineoplastic agents
Table 4: Core Diagnostic Criteria for Chemotherapy-Induced Peripheral Neuropathy
Table 5: Evaluations that should be performed prior to prescribing an analgesic in elderly patients
Table 6: Total Incident Population of CIPN in the G8 Countries (2016-2027)
Table 7: Total Incident Population of CIPN in the US (2016-2027)
Table 8: Severity Specific Incidence of CIPN in the US (2016-2027)
Table 9: Incident Population of CIPN by Chemotherapeutic Agents in the US (2016-2027)
Table 10: Total Incident Population of CIPN in Germany (2016-2027)
Table 11: Severity Specific Incidence of CIPN in Germany (2016-2027)
Table 12: Incident Population of CIPN by Chemotherapeutic Agents in Germany (2016-2027)
Table 13: Total Incident Population of CIPN in France (2016-2027)
Table 14: Severity Specific Incidence of CIPN in France (2016-2027)
Table 15: Incident Population of CIPN by Chemotherapeutic Agents in France (2016-2027)
Table 16: Total Incident Population of CIPN in Italy (2016-2027)
Table 17: Severity Specific Incidence of CIPN in Italy (2016-2027)
Table 18: Incident Population of CIPN by Chemotherapeutic Agents in Italy (2016-2027)
Table 19: Total Incident Population of CIPN in Spain (2016-2027)
Table 20: Severity Specific Incidence of CIPN in Spain (2016-2027)
Table 21: Incident Population of CIPN by Chemotherapeutic Agents in Spain (2016-2027)
Table 22: Total Incident Population of CIPN in the UK (2016-2027)
Table 23: Severity Specific Incidence of CIPN in the UK (2016-2027)
Table 24: Incident Population of CIPN by Chemotherapeutic Agents in the UK (2016-2027)
Table 25: Total Incident Population of CIPN in the Japan (2016-2027)
Table 26: Severity Specific Incidence of CIPN in the Japan (2016-2027)
Table 27: Incident Population of CIPN by Chemotherapeutic Agents in the Japan (2016-2027)
Table 28: Total Incident Population of CIPN in China (2016-2027)
Table 29: Severity Specific Incidence of CIPN in China (2016-2027)
Table 30: Incident Population of CIPN by Chemotherapeutic Agents in China (2016-2027)
Table 31: Guidelines for the Treatment for CIPN: American Society of Clinical Oncology Clinical Practice
Table 32: Guidelines for the Pharmacologic Management of Neuropathic Pain
Table 33: Advantages and disadvantages of analgesics
Table 34: Initial and maximum doses of agents used to treat NeP based on the recommendations by the JSPC 2016 and IASP 2007
Table 35: Emerging Drugs Analysis
Table 36: Emerging Drugs Analysis (Continued)
Table 37: Emerging Drugs Analysis (Continued)
Table 38: Emerging Drugs Analysis (Continued)
Table 39: SP-04 (PledOx),Clinical Trial Description, 2018
Table 40: Tetrodotoxin (TTX),Clinical Trial Description, 2018
Table 41: E-52862, Clinical Trial Description, 2018
Table 42: KRN5500,Clinical Trial Description, 2018
Table 43: NIAGEN, Clinical Trial Description, 2018
Table 44: Market Size of CIPN in G8 Countries in USD Million (2016-2027)
Table 45: Market Size of CIPN by therapies in G8 Countries in USD Million (2016-2027)
Table 46: The US Market Size of CIPN in USD Million (2016-2027)
Table 47: Market Size of CIPN by therapies in the US in USD Million (2016-2027)
Table 48: Germany Market Size of CIPN in USD Million (2016-2027)
Table 49: Market Size of CIPN by therapies in Germany in USD Million (2016-2027)
Table 50: France Market Size of CIPN in USD Million (2016-2027)
Table 51: Market Size of CIPN by therapies in France in USD Million (2016-2027)
Table 52: Italy Market Size of CIPN in USD Million (2016-2027)
Table 53: Market Size of CIPN by therapies in Italy in USD Million (2016-2027)
Table 54: Spain Market Size of CIPN in USD Million (2016-2027)
Table 55: Market Size of CIPN by therapies in Spain in USD Million (2016-2027)
Table 56: The UK Market Size of CIPN in USD Million (2016-2027)
Table 57: Market Size of CIPN by therapies in the UK in USD Million (2016-2027)
Table 58: Japan Market Size of CIPN in USD Million (2016-2027)
Table 59: Market Size of CIPN by therapies in Japan in USD Million (2016-2027)
Table 60: Market Size of CIPN in China, in USD Million (2016-2027)
Table 61: Market Size of CIPN by therapies in China in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Clinical Presentation of CIPN
Figure 2: Total Incident Population of CIPN in the G8 Countries (2016-2027)
Figure 3: Total Incident Population of CIPN in the US (2016-2027)
Figure 4: Severity Specific Incidence of CIPN in the US (2016-2027)
Figure 5: Incident Population of CIPN by Chemotherapeutic Agents in the US (2016-2027)
Figure 6: Total Incident Population of CIPN in Germany (2016-2027)
Figure 7: Severity Specific Incidence of CIPN in Germany (2016-2027)
Figure 8: Incident Population of CIPN by Chemotherapeutic Agents in Germany (2016-2027)
Figure 9: Total Incident Population of CIPN in France (2016-2027)
Figure 10: Severity Specific Incidence of CIPN in France (2016-2027)
Figure 11: Incident Population of CIPN by Chemotherapeutic Agents in France (2016-2027)
Figure 12: Total Incident Population of CIPN in Italy (2016-2027)
Figure 13: Severity Specific Incidence of CIPN in Italy (2016-2027)
Figure 14: Incident Population of CIPN by Chemotherapeutic Agents in Italy (2016-2027)
Figure 15: Total Incident Population of CIPN in Spain (2016-2027)
Figure 16: Severity Specific Incidence of CIPN in Spain (2016-2027)
Figure 17: Incident Population of CIPN by Chemotherapeutic Agents in Spain (2016-2027)
Figure 18: Total Incident Population of CIPN in the UK (2016-2027)
Figure 19: Severity Specific Incidence of CIPN in the UK (2016-2027)
Figure 20: Incident Population of CIPN by Chemotherapeutic Agents in the UK (2016-2027)
Figure 21: Total Incident Population of CIPN in the Japan (2016-2027)
Figure 22: Severity Specific Incidence of CIPN in the Japan (2016-2027)
Figure 23: Incident Population of CIPN by Chemotherapeutic Agents in the Japan (2016-2027)
Figure 24: Total Incident Population of CIPN in China (2016-2027)
Figure 25: Severity Specific Incidence of CIPN in China (2016-2027)
Figure 26: Incident Population of CIPN by Chemotherapeutic Agents in China (2016-2027)
Figure 27: Pain intensity and analgesics available in Japan
Figure 28: Unmet Needs of Chemotherapy-Induced Peripheral Neuropathy
Figure 29: Market Size of CIPN in G8 Countries in USD Million (2016-2027)
Figure 30: Market Size of CIPN by therapies in G8 Countries in USD Million (2016-2027)
Figure 31: Market Size of CIPN in the US, USD Millions (2016-2027)
Figure 32: Market Size of CIPN by therapies in US in USD Million (2016-2027)
Figure 33: Market Size of CIPN in Germany, USD Millions (2016-2027)
Figure 34: Market Size of CIPN by therapies in Germany in USD Million (2016-2027)
Figure 35: Market Size of CIPN in France, USD Millions (2016-2027)
Figure 36: Market Size of CIPN by therapies in France in USD Million (2016-2027)
Figure 37: Market Size of CIPN in Italy, USD Millions (2016-2027)
Figure 38: Market Size of CIPN by therapies in Italy in USD Million (2016-2027)
Figure 39: Market Size of CIPN in Spain, USD Millions (2016-2027)
Figure 40: Market Size of CIPN by therapies in Spain in USD Million (2016-2027)
Figure 41: Market Size of CIPN in the UK, USD Millions (2016-2027)
Figure 42: Market Size of CIPN by therapies in the UK in USD Million (2016-2027)
Figure 43: Market Size of CIPN in the Japan, USD Millions (2016-2027)
Figure 44: Market Size of CIPN by therapies in Japan in USD Million (2016-2027)
Figure 45: Market Size of CIPN in China, USD Millions (2016-2027)
Figure 46: Market Size of CIPN by therapies in China in USD Million (2016-2027)
Figure 47: Market Drivers
Figure 48: Market Barriers
Table 49: Market Size of CIPN by therapies in Germany in USD Million (2016-2027)
Table 50: France Market Size of CIPN in USD Million (2016-2027)
Table 51: Market Size of CIPN by therapies in France in USD Million (2016-2027)
Table 52: Italy Market Size of CIPN in USD Million (2016-2027)
Table 53: Market Size of CIPN by therapies in Italy in USD Million (2016-2027)
Table 54: Spain Market Size of CIPN in USD Million (2016-2027)
Table 55: Market Size of CIPN by therapies in Spain in USD Million (2016-2027)
Table 56: The UK Market Size of CIPN in USD Million (2016-2027)
Table 57: Market Size of CIPN by therapies in the UK in USD Million (2016-2027)
Table 58: Japan Market Size of CIPN in USD Million (2016-2027)
Table 59: Market Size of CIPN by therapies in Japan in USD Million (2016-2027)
Table 60: Market Size of CIPN in China, in USD Million (2016-2027)
Table 61: Market Size of CIPN by therapies in China in USD Million (2016-2027)
Figure 1: Clinical Presentation of CIPN
Figure 2: Total Incident Population of CIPN in the G8 Countries (2016-2027)
Figure 3: Total Incident Population of CIPN in the US (2016-2027)
Figure 4: Severity Specific Incidence of CIPN in the US (2016-2027)
Figure 5: Incident Population of CIPN by Chemotherapeutic Agents in the US (2016-2027)
Figure 6: Total Incident Population of CIPN in Germany (2016-2027)
Figure 7: Severity Specific Incidence of CIPN in Germany (2016-2027)
Figure 8: Incident Population of CIPN by Chemotherapeutic Agents in Germany (2016-2027)
Figure 9: Total Incident Population of CIPN in France (2016-2027)
Figure 10: Severity Specific Incidence of CIPN in France (2016-2027)
Figure 11: Incident Population of CIPN by Chemotherapeutic Agents in France (2016-2027)
Figure 12: Total Incident Population of CIPN in Italy (2016-2027)
Figure 13: Severity Specific Incidence of CIPN in Italy (2016-2027)
Figure 14: Incident Population of CIPN by Chemotherapeutic Agents in Italy (2016-2027)
Figure 15: Total Incident Population of CIPN in Spain (2016-2027)
Figure 16: Severity Specific Incidence of CIPN in Spain (2016-2027)
Figure 17: Incident Population of CIPN by Chemotherapeutic Agents in Spain (2016-2027)
Figure 18: Total Incident Population of CIPN in the UK (2016-2027)
Figure 19: Severity Specific Incidence of CIPN in the UK (2016-2027)
Figure 20: Incident Population of CIPN by Chemotherapeutic Agents in the UK (2016-2027)
Figure 21: Total Incident Population of CIPN in the Japan (2016-2027)
Figure 22: Severity Specific Incidence of CIPN in the Japan (2016-2027)
Figure 23: Incident Population of CIPN by Chemotherapeutic Agents in the Japan (2016-2027)
Figure 24: Total Incident Population of CIPN in China (2016-2027)
Figure 25: Severity Specific Incidence of CIPN in China (2016-2027)
Figure 26: Incident Population of CIPN by Chemotherapeutic Agents in China (2016-2027)
Figure 27: Pain intensity and analgesics available in Japan
Figure 28: Unmet Needs of Chemotherapy-Induced Peripheral Neuropathy
Figure 29: Market Size of CIPN in G8 Countries in USD Million (2016-2027)
Figure 30: Market Size of CIPN by therapies in G8 Countries in USD Million (2016-2027)
Figure 31: Market Size of CIPN in the US, USD Millions (2016-2027)
Figure 32: Market Size of CIPN by therapies in US in USD Million (2016-2027)
Figure 33: Market Size of CIPN in Germany, USD Millions (2016-2027)
Figure 34: Market Size of CIPN by therapies in Germany in USD Million (2016-2027)
Figure 35: Market Size of CIPN in France, USD Millions (2016-2027)
Figure 36: Market Size of CIPN by therapies in France in USD Million (2016-2027)
Figure 37: Market Size of CIPN in Italy, USD Millions (2016-2027)
Figure 38: Market Size of CIPN by therapies in Italy in USD Million (2016-2027)
Figure 39: Market Size of CIPN in Spain, USD Millions (2016-2027)
Figure 40: Market Size of CIPN by therapies in Spain in USD Million (2016-2027)
Figure 41: Market Size of CIPN in the UK, USD Millions (2016-2027)
Figure 42: Market Size of CIPN by therapies in the UK in USD Million (2016-2027)
Figure 43: Market Size of CIPN in the Japan, USD Millions (2016-2027)
Figure 44: Market Size of CIPN by therapies in Japan in USD Million (2016-2027)
Figure 45: Market Size of CIPN in China, USD Millions (2016-2027)
Figure 46: Market Size of CIPN by therapies in China in USD Million (2016-2027)
Figure 47: Market Drivers
Figure 48: Market Barriers
Table 49: Market Size of CIPN by therapies in Germany in USD Million (2016-2027)
Table 50: France Market Size of CIPN in USD Million (2016-2027)
Table 51: Market Size of CIPN by therapies in France in USD Million (2016-2027)
Table 52: Italy Market Size of CIPN in USD Million (2016-2027)
Table 53: Market Size of CIPN by therapies in Italy in USD Million (2016-2027)
Table 54: Spain Market Size of CIPN in USD Million (2016-2027)
Table 55: Market Size of CIPN by therapies in Spain in USD Million (2016-2027)
Table 56: The UK Market Size of CIPN in USD Million (2016-2027)
Table 57: Market Size of CIPN by therapies in the UK in USD Million (2016-2027)
Table 58: Japan Market Size of CIPN in USD Million (2016-2027)
Table 59: Market Size of CIPN by therapies in Japan in USD Million (2016-2027)
Table 60: Market Size of CIPN in China, in USD Million (2016-2027)
Table 61: Market Size of CIPN by therapies in China in USD Million (2016-2027)
